LEADER 04149nam 2201129z- 450 001 9910557498903321 005 20231214133211.0 035 $a(CKB)5400000000042842 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68603 035 $a(EXLCZ)995400000000042842 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug Delivery of siRNA Therapeutics 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (288 p.) 311 $a3-03936-200-3 311 $a3-03936-201-1 330 $aThe new frontier of pharmaceutical sciences is gene therapy, which is the use of molecules able to interact directly with the expression of the genetic material of the patient as well as of the disease-causing guest (bacteria, virus, parasites, and tumor cells). Among the molecules of interest for gene therapy, a relevant role is played by small interfering RNA (siRNA) molecules able to interfere with the expression of genes of interest for some diseases. However, siRNA molecules, even if they are powerful as drugs, are difficult to deliver since they are sensitive to enzymes present in plasma and they are large and negatively charged, so are difficult to administer into the cell nuclei, since the cell walls are scarcely permeable to large molecules and are also negatively charged. Therefore, the focus of research on siRNA-based therapies is their delivery, which can be performed by chemical modification, association with aptamers or polycations, or embedding them into properly designed liposomes. This book is centered on the more recent development in siRNA delivery techniques toward the clinical applications of this potent class of drugs. 606 $aMedicine$2bicssc 610 $aoligonucleotide delivery 610 $alight-activated release 610 $aintracellular release 610 $aliposome 610 $aindocyanine green 610 $adrug co-delivery 610 $amethotrexate 610 $asiRNA 610 $aantitumor effect 610 $amixed micelles 610 $atargeted delivery system 610 $acationic liposome 610 $afolate 610 $afolate receptor 610 $acationic cholesterol derivative 610 $asiRNA delivery 610 $agene knockdown 610 $atumor-targeting 610 $aVEGFA 610 $aVEGFR1 610 $aendoglin 610 $apeptide 610 $aangiogenesis 610 $agene silencing 610 $amigration 610 $aproliferation 610 $aendothelial cells 610 $aRNAi therapeutics 610 $aamphiphilic dendrons 610 $aPAMAM dendrimers 610 $aself-assembling 610 $ananovectors 610 $acovalent dendrimers 610 $aNABDs 610 $aliposomes 610 $aclinical trials 610 $adrug delivery 610 $ananoparticle 610 $acarbonate apatite 610 $aERBB2 610 $aAKT 610 $abreast cancer 610 $aovarian cancer 610 $apolymer 610 $alipid 610 $adelivery 610 $apoly(ethylene) imine 610 $aPEI 610 $aRNA 610 $atyrosine-modification 610 $atumor xenograft 610 $amagnetic nanoparticle 610 $airon oxide 610 $aBCL2 610 $aBIRC5/survivin 610 $aoral cancer 610 $aaptamers 610 $acancer 610 $ananoparticles 610 $aSTAT6 610 $apolyaspartamide 610 $apegylation 610 $apolyamine 610 $apolyplexes 610 $aasthma 615 7$aMedicine 700 $aLamberti$b Gaetano$4edt$023147 702 $aAngela Barba$b Anna$4edt 702 $aLamberti$b Gaetano$4oth 702 $aAngela Barba$b Anna$4oth 906 $aBOOK 912 $a9910557498903321 996 $aDrug Delivery of siRNA Therapeutics$93021406 997 $aUNINA